Ngm Biopharmaceuticals Inc

NASDAQ:NGM   3:59:55 PM EDT
27.85
-0.75 (-2.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.05B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$21.97 Million
Adjusted EPS-$0.46
See more estimates
10-Day MA$27.81
50-Day MA$26.18
200-Day MA$20.53
See more pivots

NGM BIOPHARMACEUTICALS INC Stock, NASDAQ:NGM

333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080
United States of America
Phone: 650-243-5555
Number of Employees:

Description

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.